Acting for an ad hoc group of credit funds and banks in respect of the restructuring of US$370M indebtedness of Wollongong Coal Limited, a mining business listed on the Australian Stock Exchange and its controlling shareholder, Jindal Steel and Power (Australia) Pty Ltd through schemes of arrangement sanctioned by the Supreme Court of New South Wales. This transaction was named “Insolvency and Restructuring Deal of the Year” by the Australasian Law Awards 2020
Acting for Centurium Capital in respect of its US$240M financing of Luckin Coffee Inc. to facilitate the implementation of the restructuring of Luckin Coffee’s indebtedness
Advising a consortium of private credit investors on the refinancing and restructuring of the US$235M indebtedness of Nixon Investments Pte. Ltd. (a subsidiary of PT Astrindo Nusantara Infrastruktur Tbk., an energy infrastructure company listed in Indonesia)
Represented Bain Capital Credit in relation to various portfolio investments
Represented a credit fund in relation to bespoke sub-participation arrangements on certain loan portfolios
Advising a consortium of credit investors on a one -time settlement (OTS) with existing lenders to a leading power company
Acting for Sea Limited (NYSE: SE), a leading global consumer internet company, in the acquisition by its digital entertainment arm, Garena, of Phoenix Labs, an acclaimed independent games development company founded in Vancouver
Represented Bain Capital in its significant minority investment in Maxford Group, a leading surface treatment and material processing company with multiple processing facilities across Asia, and its related arrangements with CNI Group, the controlling shareholder of Maxford
Acting for KKR in the leveraged financing for the acquisition of the NVC Lighting business in China
Acting for Magnum Opus Acquisition Limited (NYSE: OPA), a publicly traded special purpose acquisition company, on its business combination with Forbes Global Media Holdings Inc., the iconic business information brand
Acting for Eddingpharm, a Chinese specialty pharmaceutical company, in its debt financing to purchase two legacy antibiotic brands (Ceclor® and Vancocin®), and a manufacturing facility from Eli Lilly and Company (NYSE: LLY)
